Citations

Clear

61 citation(s) found for "Nguyen, Minh".

PATH-08. MOLECULAR DIVERGENCE RATES DIFFER BETWEEN BRAIN METASTASES AND EXTRACRANIAL DISEASE SITES ACROSS PRIMARY TUMOR HISTOLOGIES
Young, Jacob, Malik, Noor Ul Ain , Parney, Ian, Chang, Edward, Berger, Mitchel S. , Theodosopoulos, Philip V. , Hervey‐Jumper, Shawn L. , Vasudevan, Harish N. , Malik, Noor , Malik, Noor , Morshed, Ramin A. , Khela, Harmon Singh , Nguyen, Minh, Goldschmidt, Ezequiel , McDermott, Michael , Malik, Noor, Chang, Edward, Huppert, Laura Ann , Aghi, Manish Kumar

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii179-viii179

10.1093/neuonc/noae165.0707 Get It

Abstract Genomic alterations and molecular subgroups between extracranial disease sites and brain metastases often differ, yet the prevalence and clinical significance of divergent evolution in brain metastases is not fully understood. This study examined genomic alterations and molecular subgroup divergence rates between matched brain metastases and extracranial disease sites. A retrospective, two-center study was conducted on patients who underwent resection of brain metastases between 2014-2022 with clinical and matched genomic data and/or molecular markers available. The overall cohort comprised 256 patients with matched tumors from multiple cancer types, most commonly from breast (n=108, 42.2%), melanoma (n=83, 32.4%), and NSCLC (n=43, 16.8%). Targeted next-generation sequencing of over 500 oncogenes was performed on resected tumors as part of clinical care (n=41 patients with matched specimens). Molecular subgroups for breast, melanoma, and non-small cell lung cancer were also assessed by immunohistochemistry to evaluate rates of molecular subgroup discordance between sites. Subgroup discordance by immunohistochemistry was observed most frequently across breast cancer (22.2%, n=24/108) with loss of the estrogen receptor (ER) and progesterone receptor (PR) and gain of HER2 most frequently observed within brain metastases. Molecular subgroup discordance was rare within melanoma (7.3%, n=6/82) and NSCLC (14.0%, n=6/43) patients. When evaluating oncogenomic alterations from targeted DNA sequencing in 41 patients with matched specimens, 80.5% (33/41) of brain metastases demonstrated a unique oncogene alteration profile compared to an extracranial disease site. Fourteen patients (34.1%) had a gain of at least 1 targetable alteration within a brain metastasis that was not observed in an extracranial disease site. Brain metastases demonstrated high rates of genomic divergence compared to primary and extracranial metastatic disease sites. This data supports obtaining brain metastasis tissue and conducting molecular profiling of this tissue to help select optimal CNS penetrant systemic therapies for each patient.
EPID-09. THE NATURAL HISTORY AND MOLECULAR ARCHITECTURE OF INCIDENTAL MENINGIOMAS
Mirchia, Kanish , Raleigh, David R. , Nguyen, Minh , Chen, William C. , Magill, Stephen T. , Morshed, Ramin A.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii139-viii139

10.1093/neuonc/noae165.0545 Get It

Abstract The prevalence of asymptomatic, incidental meningiomas is increasing due to greater frequency of brain imaging. This retrospective cohort study of adult patients presenting at a single institution from 1996-2020 integrated clinical data, serial magnetic resonance imaging (MRI) volumetrics, DNA methylation profiling, and targeted gene expression profiling to define the natural history and molecular architecture of incidental meningiomas. Volumetrics were calculated from contrast-enhanced brain MRIs at time of diagnosis compared to serial surveillance MRIs (average 3 MRIs per patient pre-intervention, range: 1-12) DNA methylation groups and gene expression risk scores were defined for 123 samples that underwent resection. Time-to-event analyses were performed for progression-free survival (PFS), symptom-free survival (SFS), and treatment-free survival (TFS). The cohort included 238 meningiomas from 207 patients. Median age at diagnosis was 59 years and 81.5% of patients were female. Median clinical and imaging follow-up were 9.1 and 6.7 years, respectively, during which time 50.8% progressed. Median maximum diameter and volume at diagnosis were 2.20 cm and 4.25 cm3, respectively, and median pre-treatment volumetric growth rate was 19.2% per year. Median pre-treatment PFS and TFS were 3.10 and 1.27 years, respectively, and median SFS and post-treatment PFS were not reached. Cox proportional hazards regression identified maximum diameter at diagnosis as a significant predictor of worse pre-treatment PFS (multivariate HR 1.65 per 1 cm [95% CI 1.19–2.28], p=0.0027) and worse TFS (multivariate HR 1.44 per 1 cm [95% CI 1.17–1.76], p<0.001). Skull base tumors had with worse SFS (multivariate HR 2.48 [95% CI 1.02–6.00], p=0.045). Molecular and histological features among incidental meningiomas that ultimately underwent resection (n=176, 74.0%) were reassuring (89.2% WHO grade 1, 10.2% WHO grade 2). These findings suggest maximum diameter at diagnosis of incidental meningiomas is significantly associated with earlier progression and eventual treatment, and skull base tumors have earlier symptom development.
NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors
Eschbacher, Kathryn L. , Tran, Quynh T. , Moskalev, Evgeny A. , Jenkins, Sarah M. , Fritchie, Karen , Stoehr, Robert , Caron, Alissa, Link, Michael J., Brown, Paul D. , Guajardo, Andrew, Wu, Ashley, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Nguyen, Minh , Gross, John , Vega, Jose Velazquez, Haller, Florian , Louis, David N , Giannini, Caterina , Link, Michael J. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Martinez‐Lage, Maria , Orr, Brent A. , Giannini, Caterina

Mayo Clinic

Brain Pathology | March 25, 2024 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/bpa.13256 | PMID 38523251 Get It

AbstractMeningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal SFTs with extended clinical follow‐up (median 9.9 years; range 15 days–43 years), we performed extensive molecular characterization including genome‐wide DNA methylation profiling (n = 80) and targeted TERT promoter mutation testing (n = 98). Associations were examined with NAB2::STAT6 fusion status (n = 101 cases; 51 = ex5‐7::ex16‐17, 26 = ex4::ex2‐3; 12 = ex2‐3::exANY/other and 12 = no fusion) and placed in the context of 2021 Central Nervous System (CNS) WHO grade. NAB2::STAT6 fusion breakpoints (fusion type) were significantly associated with metastasis‐free survival (MFS) (p = 0.03) and, on multivariate analysis, disease‐specific survival (DSS) when adjusting for CNS WHO grade (p = 0.03). DNA methylation profiling revealed three distinct clusters: Cluster 1 (n = 38), Cluster 2 (n = 22), and Cluster 3 (n = 20). Methylation clusters were significantly associated with fusion type (p < 0.001), with Cluster 2 harboring ex4::ex2‐3 fusion in 16 (of 20; 80.0%), nearly all TERT promoter mutations (7 of 8; 87.5%), and predominantly an “SFT” histologic phenotype (15 of 22; 68.2%). Clusters 1 and 3 were less distinct, both dominated by tumors having ex5‐7::ex16‐17 fusion (respectively, 25 of 33; 75.8%, and 12 of 18; 66.7%) and with variable histological phenotypes. Methylation clusters were significantly associated with MFS (p = 0.027), but not overall survival (OS). In summary, NAB2::STAT6 fusion type was significantly associated with MFS and DSS, suggesting that tumors with an ex5::ex16‐17 fusion may have inferior patient outcomes. Methylation clusters were significantly associated with fusion type, TERT promoter mutation status, histologic phenotype, and MFS.
Breast Implant–Associated Anaplastic Large Cell Lymphoma Awareness: An Analysis of the Responses to an Institutional Campaign and Global Recall
Mason, Madeleine M., Zheng, Eugene E. , Kerivan, Lauren, Nguyen, Minh-Doan T. , Kerivan, Lauren T, Kuruoglu, Doga

Mayo Clinic

Annals of Plastic Surgery | October 12, 2023 | Volume: 91 | Issue: 5 | Pages: 529-533

10.1097/sap.0000000000003689 | PMID 37823619 Get It

Background We performed an assessment of patient response rates and clinical outcomes to the global recall for textured breast implants and to our institution's letters informing them of their risk of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Methods A retrospective review of patients who had textured implants placed at our institution was completed. Outcome measures included patient response rates to either the global recall or our institution's letters, rate of textured implant removal, and type of subsequent revision surgery. Results A total of 1176 patients with textured implants were reviewed for this study. In total, 374 patients (31.8%) reached out to discuss their risk of BIA-ALCL, and 297 (25.3%) eventually presented to the clinic. One hundred twenty eight patients (34.2%) responded after the letter but before the US Food and Drug Administration (FDA) ban of macrotextured BIOCELL implants, 186 (49.7%) after the FDA ban, and 48 (12.8%) after the manufacturer's multichannel campaign. One hundred eighteen patients with textured implants (11.6%) proceeded with surgery. Most underwent exchange with smooth implants (76 patients [64.4%]) after textured implant removal. Conclusions A significant portion of patients (31.8%) responded to our letters, the FDA ban, and the manufacturer's campaign. Despite the low incidence of BIA-ALCL and the ongoing recommendation for observation in the setting of no symptoms, 11.6% of our patients still elected to proceed with implant removal. Exchange to smooth implants was the most popular surgical option at 64.4%.
Statement from the Asia Summit: Current state of arrhythmia care in Asia
Agbayani, Michael‐Joseph F., Choi, Jong‐Il , Dan, Van Buu , Hanafy, Dicky A, Hurwitz, Jodie L. , Kalman, Jonathan M. , Khan, Aamir Hameed H., Khmao, Pichmanil , Ngarmukos, Tachapong , Nguyen, Son Thai Binh, Nwe, Nwe, Soejima, Kyoko , Stiles, Martin K. , TSAO, HSUAN‐MING , Tseveendee, Saruul, Shimizu, Wataru , Kusumoto, Fred , Apiyasawat, Sirin , Chen, Ming-Long , Ching, Chi Keong , Hanafy, Dicky Armein , Johar, Sofian , Krahn, Andrew D. , Nwe, Nwe, Oh, Seil

Mayo Clinic

Journal of Arrhythmia | September 27, 2023 | Volume: 40 | Issue: 1 | Pages: 1-16

10.1002/joa3.12935 Get It

AbstractOn May 27, 2022, the Asia Pacific Heart Rhythm Society and the Heart Rhythm Society convened a meeting of leaders from different professional societies of healthcare providers committed to arrhythmia care from the Asia Pacific region. The overriding goals of the meeting were to discuss clinical and health policy issues that face each country for providing care for patients with electrophysiologic issues, share experiences and best practices, and discuss potential future solutions. Participants were asked to address a series of questions in preparation for the meeting. The format of the meeting was a series of individual country reports presented by the leaders from each of the professional societies followed by open discussion. The recorded presentations from the Asia Summit can be accessed at https://www.heartrhythm365.org/URL/asiasummit‐22. Three major themes arose from the discussion. First, the major clinical problems faced by different countries vary. Although atrial fibrillation is common throughout the region, the most important issues also include more general issues such as hypertension, rheumatic heart disease, tobacco abuse, and management of potentially life‐threatening problems such as sudden cardiac arrest or profound bradycardia. Second, there is significant variability in the access to advanced arrhythmia care throughout the region because of differences in workforce availability, resources, drug availability, and national health policies. Third, collaboration in the area already occurs between individual countries, but no systematic regional method for working together is present.
Abstract 14719: Erk5 S496 Phosphorylation, but Not Erk5 Kinase Activation, Promotes Senescence-Associated Cell Growth (sacg) and Inflammation of Myeloid Cells and Atherosclerosis via Upregulating Sumoylation at a Novel Site (k518) on Nrf2 and Aryl Hydrocar
Li, Shengyu, Ko, Kyung Ae , Samanthapudi, Venkata Subrahman K, Lee, Ling-Ling, Herrmann, Joerg , Shoykhet, Michael N, Shen, Ying H. , Schadler, Keri , Yoshimoto, Momoko, Fujiwra, Keigi, Le, Nhat Tu, Kotla, Sivareddy , Imanishi, Masaki , Zhang, Aijun , Lin, Steven H. , Shen, Ying H , Schadler, Keri , Nguyen, Minh T, Gupte, Anisha A. , Reyes‐Gibby, Cielito C. , Yeung, Sai‐Ching J. , Palaskas, Nicolas L , Cooke, John P. , Pownall, Henry J. , Fujiwra, Keigi, Hamilton, Dale J. , Burks, Jared K , Wang, Guangyu , Abe, Jun-Ichi

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.14719 Get It

Senescence induced by various stresses reprograms cancer cells to acquire senescence-associated (SA) cell growth (SACG), which allows them to escape senescence-induced cell cycle arrest with enhanced growth potential. ERK5 is a dual kinase-transcription factor, containing an N-terminal kinase domain and transactivation domains in the C-terminal half. Recent data have raised questions regarding the functional role of ERK5 kinase inhibitors in cancer and inflammatory diseases. We aimed to investigate how ERK5 reprograms myeloid cells (MC) to the SA secretory phenotype (SASP) and SACG, consequently leading to atherosclerosis (AthS). AthS was inhibited in ERK5 S496A knock-in (KI) mice. Single-cell analysis of p53 and Ki67 with imaging mass cytometry revealed three groups of MCs with different p53 and Ki67 expression patterns in the plaque. One group showed that p53 and Ki67 were co-expressed lineally, suggesting that this group of cells escaped from the growth-suppression effects of p53, which is also known as a senescence marker. The % of ERK5 S496A KI cells in this group was significantly lower than in wild-type (WT). Also, we found an increase of SA β-gal (SAβ-gal) + Ki67 + and 53BP1 + Ki67 + cells in bone narrow-derived macrophage (BMDMs) isolated from hypercholesterolemia (H-chol) WT mice, suggesting H-chol-induced MC SACG. MC SACG were significantly inhibited in ERK5 S496A KI mice, supporting the role of ERK5 S496 phosphorylation on SACG. RNA sequencing analysis identified the ERK5 S496 phosphorylation-dependent AHR induction by H-chol, and AHR depletion significantly inhibited SACG. We also discovered a critical effect of ERK5 S496 phosphorylation on SUMOylation at a novel site of NRF2 (i.e., K518), which inhibited NRF2 transcriptional activity without affecting ERK5 kinase activity and antagonized oxidized LDL (oxLDL)-induced SASP. Specific ERK5 kinase inhibitors (AX15836 and XMD8-92) inhibited oxLDL-induced ERK5 S496 phosphorylation, suggesting that ERK5 S496 phosphorylation was involved at least in part of the effects of these inhibitors. We have discovered a novel mechanism in which ERK5 S496 phosphorylation directly inhibits NRF2 activity by upregulating NRF2 K518 SUMOylation and AHR induction, subsequently inducing SACG and AthS.
An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis
Abe, Jun‐ichi , Imanishi, Masaki , Li, Shengyu , Zhang, Aijun , Ko, Kyung Ae , Samanthapudi, Venkata Subrahman K, Lee, Ling-Ling, Bojorges, Angelica Paniagua, Gi, Young Jin , Hobbs, Brian P. , Herrmann, Joerg , Chini, Eduardo N. , Shen, Ying H. , Schadler, Keri , Nguyen, Thi-Hong-Minh, Gupte, Anisha A. , Reyes‐Gibby, Cielito C. , Abe, Rei , Pownall, Henry J. , Yoshimoto, Momoko , Fujiwara, Keigi , Hamilton, Dale J. , Le, Nhat-Tu , Kotla, Sivareddy , Li, Shengyu , Deswal, Anita M , Shen, Ying H , Reyes-Gibby, Cielito , Abe, Rei J , Dantzer, Robert , Palaskas, Nicolas L , Cooke, John P , Pownall, Henry J , Yoshimoto, Momoko , Fujiwara, Keigi , Hamilton, Dale J , Burks, Jared K , Wang, Guangyu , Kotla, Sivareddy , Abe, Jun-Ichi , Li, Shengyu , Zhang, Aijun , Lin, Steven H. , Schadler, Keri , Yeung, Sai‐Ching J. , Olmsted‐Davis, Elizabeth A. , Krishnan, Sunil , Cooke, John P. , Wang, Guangyu

Mayo Clinic

Circulation Research | June 2, 2023 | Volume: 133 | Issue: 1 | Pages: 25-44

10.1161/circresaha.122.322017 | PMID 37264926 Get It

Background: ERK5 (extracellular signal-regulated kinase 5) is a dual kinase transcription factor containing an N-terminal kinase domain and a C-terminal transcriptional activation domain. Many ERK5 kinase inhibitors have been developed and tested to treat cancer and inflammatory diseases. However, recent data have raised questions about the role of the catalytic activity of ERK5 in proliferation and inflammation. We aimed to investigate how ERK5 reprograms myeloid cells to the proinflammatory senescent phenotype, subsequently leading to atherosclerosis. Methods: A ERK5 S496A (dephosphorylation mimic) knock in (KI) mouse model was generated using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat–associated 9), and atherosclerosis was characterized by hypercholesterolemia induction. The plaque phenotyping in homozygous ERK5 S496A KI and wild type (WT) mice was studied using imaging mass cytometry. Bone marrow–derived macrophages were isolated from hypercholesterolemic mice and characterized using RNA sequencing and functional in vitro approaches, including senescence, mitochondria reactive oxygen species, and inflammation assays, as well as by metabolic extracellular flux analysis. Results: We show that atherosclerosis was inhibited in ERK5 S496A KI mice. Furthermore, ERK5 S496 phosphorylation mediates both senescence-associated secretory phenotype and senescence-associated stemness by upregulating AHR (aryl hydrocarbon receptor) in plaque and bone marrow–derived macrophages isolated from hypercholesterolemic mice. We also discovered that ERK5 S496 phosphorylation could induce NRF2 (NFE2-related factor 2) SUMOylation at a novel K518 site to inhibit NRF2 transcriptional activity without altering ERK5 catalytic activity and mediates oxidized LDL (low-density lipoprotein)–induced senescence-associated secretory phenotype. Specific ERK5 kinase inhibitors (AX15836 and XMD8-92) also inhibited ERK5 S496 phosphorylation, suggesting the involvement of ERK5 S496 phosphorylation in the anti-inflammatory effects of these ERK5 kinase inhibitors. Conclusions: We discovered a novel mechanism by which the macrophage ERK5-NRF2 axis develops a unique senescence-associated secretory phenotype/stemness phenotype by upregulating AHR to engender atherogenesis. The finding of senescence-associated stemness phenotype provides a molecular explanation to resolve the paradox of senescence in proliferative plaque by permitting myeloid cells to escape the senescence-induced cell cycle arrest during atherosclerosis formation.
The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge: Results after 1 Year Follow-up
Bron, Esther E. , Toga, Arthur W. , Weiner, Michael W. , Barkhof, Frederik , Fox, Nick C. , Eshaghi, Arman , Toni, Tina, Salaterski, Marcin, Lunina, Veronika, Ansart, Manon , Lu, Pascal , Thompson, Wesley K., Nahon, Aviv, Levy, Yarden, Halbersberg, Dan, Cohen, Mariya, Liao, Huiling , Yu, Kaixian , Ismail, Aya, Wood, Timothy C. , Nguyen, Minh , Sun, Nanbo , Yeo, B.T. Thomas , Qi, Ke , Chen, Shiyang , Qiu, Deqiang , Buciuman, Ionut, Kelner, Alex, Rimocea, Denisa, Ourselin, Sébastien , Venkatraghavan, Vikram , Liu, Keli , Rabe, Christina, Manser, Paul T. , Howlett, James , Huang, Zhiyue , Mukherjee, Sach, Rouanet, Anaïs , Oriol, Javier de Velasco , Clemente, Edgar E. V., Estrada, Karol , Altmann, André , Stonnington, Cynthia M. , Wu, Jianfeng , Devadas, Vivek, Fourrier, Clémentine , Doshi, Jimit , Moore, Paul J. , Lyons, Terry , Ciszek, Robert, Jedynak, Bruno , Pandya, K., Engels, William R., Cole, Joseph B., Golland, Polina , Alexander, Daniel C. , Initiative, The Alzheimer's Disease Neuroimaging, Toga, Arthur W , Barkhof, Frederik , Fox, Nick C , Weiner, Michael W , Marinescu, Razvan Valentin , Oxtoby, Neil P. , Young, Alexandra L. , Durrleman, Stanley , Iddi, Samuel , Li, Dan , Donohue, Michael , Li, Tengfei , Zhu, Hongtu , Tamez‐Peña, José G. , Wood, Timothy, Bravo, Héctor Corrada , Feng, Jiashi , Chen, Gang , Qi, Ke, Pop, Raluca, Ghazi, Mostafa Mehdipour , Nielsen, Mads , Sørensen, Lauge , Hill, Steven M., Kiddle, Steven John , Taschler, Bernd , Tom, Brian D. M. , White, Simon Richard , Faux, Noel Garry , Sedai, Suman , Aksman, Leon , Wang, Yalin , Rakêt, Lars Lau , Sotiras, Aristeidis , Erus, Güray , Davatzikos, Christos , Vogel, Jacob W. , Doyle, Andrew , Tam, Angela , Diaz-Papkovich, Alex , Jammeh, Emmanuel , Koval, Igor , Gallacher, John , Tohka, Jussi , Pandya, Kruti, Bilgel, Murat , Engels, William, Cole, Joseph, Klein, Stefan , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Machine Learning for Biomedical Imaging | May 17, 2023 | Volume: 1 | Issue: December 2021 | Pages: 1-60

10.59275/j.melba.2021-2dcc Get It

Accurate prediction of progression in subjects at risk of Alzheimer's disease is crucial for enrolling the right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for predicting disease onset and progression is currently lacking. We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk of Alzheimer's disease. Challenge participants were required to make a prediction, for each month of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer's Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. The methods used by challenge participants included multivariate linear regression, machine learning methods such as support vector machines and deep neural networks, as well as disease progression models. No single submission was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13 no single submitted prediction method was significantly better than random guesswork. Two ensemble methods based on taking the mean and median over all predictions, obtained top scores on almost all tasks. Better than average performance at diagnosis prediction was generally associated with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated with inclusion of summary statistics, such as the slope or maxima/minima of patient-specific biomarkers. On a limited, cross-sectional subset of the data emulating clinical trials, performance of the best algorithms at predicting clinical diagnosis decreased only slightly (2 percentage points) compared to the full longitudinal dataset. The submission system remains open via the website https://tadpole.grand-challenge.org, while TADPOLE SHARE (https://tadpole-share.github.io/) collates code for submissions. TADPOLE's unique results suggest that current prediction algorithms provide sufficient accuracy to exploit biomarkers related to clinical diagnosis and ventricle volume, for cohort refinement in clinical trials for Alzheimer's disease. However, results call into question the usage of cognitive test scores for patient selection and as a primary endpoint in clinical trials.
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
Raleigh, David R. , Youngblood, Mark W. , Polley, Mei‐Yin C. , Mirchia, Kanish , Won, Minhee , Harmanci, Arif , Vasudevan, Harish N. , Yu, Theresa, Bhave, Varun , Lam, Tai‐Chung , Pu, Jenny Kan-Suen, Chang, Jason Y. , Haberler, Christine , Mawrin, Christian , Rood, Brian , Chew, Jessica, Boreta, Lauren , Butowski, Nicholas , Bush, Nancy Ann Oberheim , Chandler, James P. , Rogers, Leland , Pugh, Stephanie L. , Sneed, Penny K. , Raleigh, David , Choudhury, Abrar , Youngblood, Mark , Leung, Gilberto , Palmer, Joshua D , Berghoff, Anna , Preusser, Matthias , Santagata, Sandro , Solomon, David A , Horbinski, Craig , Perry, Arie , Sahm, Felix , Chen, William C. , Lucas, Calixto‐Hope G. , Maas, Sybren L. N. , Suwala, Abigail Kora , Bayley, James C. , Harmancı, Akdes Serin , Klisch, Tiemo Jürgen , Nguyen, Minh , McCortney, Kathleen , Perlow, Haley K. , Palmer, Joshua D. , Preusser, Matthias , Nicolaides, Theodore , Agnihotri, Sameer , Resnick, Adam , Young, Jacob S. , Braunstein, Steve , Schulte, Jessica D. , Spetzler, David B. , Villanueva-Meyer, Javier E. , Solomon, David A. , Mehta, Minesh P. , Berger, Mitchel S. , Horbinski, Craig , McDermott, Michael , Perry, Arie , Bi, Wenya Linda , Patel, Akash J. , Sahm, Felix , Magill, Stephen T.

Mayo Clinic

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2663611/v1 | PMID 36993741 Get It

Abstract Background Surgery is the mainstay of treatment for meningioma, the most common primary intracranial tumor, but improvements in meningioma risk stratification are needed and current indications for postoperative radiotherapy are controversial. Recent studies have proposed prognostic meningioma classification systems using DNA methylation profiling, copy number variants, DNA sequencing, RNA sequencing, histology, or integrated models based on multiple combined features. Targeted gene expression profiling has generated robust biomarkers integrating multiple molecular features for other cancers, but is understudied for meningiomas. Methods Targeted gene expression profiling was performed on 173 meningiomas and an optimized gene expression biomarker (34 genes) and risk score (0 to 1) was developed to predict clinical outcomes. Clinical and analytical validation was performed on independent meningiomas from 12 institutions across 3 continents (N = 1856), including 103 meningiomas from a prospective clinical trial. Gene expression biomarker performance was compared to 9 other classification systems. Results The gene expression biomarker improved discrimination of postoperative meningioma outcomes compared to all other classification systems tested in the independent clinical validation cohort for local recurrence (5-year area under the curve [AUC] 0.81) and overall survival (5-year AUC 0.80). The increase in area under the curve compared to the current standard of care, World Health Organization 2021 grade, was 0.11 for local recurrence (95% confidence interval [CI] 0.07–0.17, P < 0.001). The gene expression biomarker identified meningiomas benefiting from postoperative radiotherapy (hazard ratio 0.54, 95% CI 0.37–0.78, P = 0.0001) and re-classified up to 52.0% meningiomas compared to conventional clinical criteria, suggesting postoperative management could be refined for 29.8% of patients. Conclusions A targeted gene expression biomarker improves discrimination of meningioma outcomes compared to recent classification systems and predicts postoperative radiotherapy responses.
Intraoperative Ergonomic Assessment of Exoscopes versus Conventional DIEP Flap
Wang, Tianke , Nguyen, Minh-Doan T. , Harless, Christin A., Smith, Tianqi Gao, Norasi, Hamid , Nguyen, Minh-Doan, Harless, Christin, Smith, Tianqi G, Hallbeck, Susan, Law, Katherine E. , Tetteh, Emmanuel , Hallbeck, M. Susan

Mayo Clinic

Journal of Reconstructive Microsurgery | December 13, 2022 | Volume: 39 | Issue: 06 | Pages: 453-461

10.1055/s-0042-1758188 | PMID 36509101 Get It

Abstract Background This study compared the ergonomics of surgeons during deep inferior epigastric perforator (DIEP) flap surgery using either baseline equipment (loupes, headlights, and an operating microscope) or an exoscope. Plastic surgeons may be at high risk of musculoskeletal problems. Recent studies indicate that adopting an exoscope may significantly improve surgeon postures and ergonomics. Methods Postural exposures, using inertial measurement units at the neck, torso, and shoulders, were calculated in addition to the surgeons' subjective physical and cognitive workload. An ergonomic risk score on a scale of 1 (lowest) to 4 (highest) was calculated for each of the postures observed. Data from 23 bilateral DIEP flap surgeries (10 baseline and 13 exoscope) were collected. Results The neck and torso risk scores decreased significantly during abdominal flap harvest and chest dissection, while right shoulder risk scores increased during the abdominal flap harvest for exoscope DIEP flap procedures compared with. Exoscope anastomoses demonstrated higher neck, right shoulder, and left shoulder risk scores. The results from the survey for the “surgeon at abdomen” showed that the usage of exoscopes was associated with decreased performance and increased mental demand, temporal demand, and effort. However, the results from the “surgeon at chest” showed that the usage of exoscopes was associated with lower physical demand and fatigue, potentially due to differences in surgeon preference. Conclusion Our study revealed some objective evidence for the ergonomic benefits of exoscope; however, this is dependent on the tasks the surgeon is performing. Additionally, personal preferences may be an important factor to be considered in the ergonomic evaluation of the exoscope.